BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Azorin J, Simon N. Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale. Expert Opinion on Drug Metabolism & Toxicology 2020;16:1175-86. [DOI: 10.1080/17425255.2020.1821646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Hjorth S. The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective. Front Psychiatry 2021;12:760181. [PMID: 34899422 DOI: 10.3389/fpsyt.2021.760181] [Reference Citation Analysis]
2 Rentrop M, Huhn M, Schwerthöffer D. [Clozapine in the Treatment of Schizophrenic Psychosis: Patient Characteristics and Antipsychotic Combinations in One Cohort at a Psychiatric Care Hospital]. Fortschr Neurol Psychiatr 2021. [PMID: 34384116 DOI: 10.1055/a-1526-2269] [Reference Citation Analysis]
3 Marchi M, Galli G, Magarini FM, Mattei G, Galeazzi GM. Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Metab Toxicol 2021;17:483-93. [PMID: 33538213 DOI: 10.1080/17425255.2021.1885648] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]